Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic
Lei Tian, Taotao Qiang, Chengyuan Liang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 213, pp. 113201-113201
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Florian Kabinger, Carina Stiller, Jana Schmitzová, et al.
Nature Structural & Molecular Biology (2021) Vol. 28, Iss. 9, pp. 740-746
Open Access | Times Cited: 597
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Orthogonal RNA replication enables directed evolution and Darwinian adaptation in mammalian cells
Liang Ma, Yihan Lin
Nature Chemical Biology (2025)
Closed Access | Times Cited: 1
In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis
Normi D. Gajjar, Tejas M. Dhameliya, Gaurang Shah
Journal of Molecular Structure (2021) Vol. 1239, pp. 130488-130488
Open Access | Times Cited: 74
Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase
Federico Munafò, Elisa Donati, Nicoletta Brindani, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 48
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115292-115292
Open Access | Times Cited: 26
Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches
Hafiz Muzzammel Rehman, Muhammad Sajjad, Muhammad Akhtar Ali, et al.
International Journal of Biological Macromolecules (2023) Vol. 237, pp. 124169-124169
Open Access | Times Cited: 24
In search of SARS CoV-2 replication inhibitors: Virtual screening, molecular dynamics simulations and ADMET analysis
Prinsa R. Nagar, Normi D. Gajjar, Tejas M. Dhameliya
Journal of Molecular Structure (2021) Vol. 1246, pp. 131190-131190
Open Access | Times Cited: 50
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Zheng Yao Low, Ashley Jia Wen Yip, Sunil K. Lal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 2, pp. 166294-166294
Open Access | Times Cited: 41
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic
Ross D. Jansen‐van Vuuren, Luka Jedlovčnik, Janez Košmrlj, et al.
ACS Omega (2022) Vol. 7, Iss. 46, pp. 41840-41858
Open Access | Times Cited: 36
Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi
Susanne H. Kirsch, F. P. Jake Haeckl, Rolf Müller
Natural Product Reports (2022) Vol. 39, Iss. 6, pp. 1226-1263
Closed Access | Times Cited: 28
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112700-112700
Open Access | Times Cited: 27
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities
Sha Hu, Jiong Chen, Jin-Xu Cao, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106549-106549
Closed Access | Times Cited: 18
Discovery and Rational Optimization of 2, 2'-((1h-Indole-2,3-Diyl) Bis (Thio))Diacetamide as Novel Sars-Cov-2 Rdrp Inhibitors
Yu-Cheng Wang, Yu Shi, Jian‐Yuan Zhao, et al.
(2025)
Closed Access
In silico Evaluation of H1-Antihistamine as Potential Inhibitors of SARS-CoV-2 RNA-dependent RNA Polymerase: Repurposing Study of COVID-19 Therapy
M. Bou Hamdan, Necla Kulabaş, İlkay Küçükgüzel
Turkish Journal of Pharmaceutical Sciences (2025) Vol. 21, Iss. 6, pp. 566-576
Open Access
Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7
Deepa Singh, Tushar Kushwaha, Rajkumar Kulandaisamy, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102452-102452
Open Access
The Chiral 5,6-Cyclohexane-fused Uracil Ring-System: a Molecular Platform with Promising Activity against SARS-CoV-2
Enrico Marcantonio, Debora Guazzetti, Crescenzo Coppa, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117302-117302
Closed Access
Discovery and optimization of Phenazopyridine hydrochloride as novel SARS-CoV-2 RdRp inhibitors
Jian‐Yuan Zhao, Guoning Zhang, Yasheng Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 288, pp. 117422-117422
Closed Access
Discovery and rational optimization of 2, 2′-((1H-indole-2,3-diyl) bis (thio))diacetamide as novel SARS-CoV-2 RdRp inhibitors
Yu Shi, Jian‐Yuan Zhao, Min Li, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118153-118153
Closed Access
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Florian Kabinger, Carina Stiller, Jana Schmitzová, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 37
Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
Zhonglei Wang, Liyan Yang, Xian‐En Zhao
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 4684-4701
Open Access | Times Cited: 36
Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis
Shanshan Yang, Shengshu Wang, Mingmei Du, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 3, pp. 1229-1242
Open Access | Times Cited: 26
Gossypol Broadly Inhibits Coronaviruses by Targeting RNA‐Dependent RNA Polymerases
Wenjing Wang, Wenkang Li, Zhiyuan Wen, et al.
Advanced Science (2022) Vol. 9, Iss. 35
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top